Hao Su
Impact in
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
Papers in
- Hepatology 31
- Hepatocellular Carcinoma Treatment and Prognosis 31
- Oncology 25
- Colorectal Cancer Surgical Treatments 14
- Colorectal Cancer Treatments and Studies 6
- Pancreatic and Hepatic Oncology Research 6
- Co-authors
- Huarong Chen (15 shared papers)Hongyan Gou (10 shared papers)Jun Qing Yu (10 shared papers)Tao Peng (37 shared papers)Chuangye Han (34 shared papers)Guangzhi Zhu (37 shared papers)Xiwen Liao (33 shared papers)Jianning Zhai (3 shared papers)
- Journals
- Cancer Management and Research (7 papers)Journal of Cancer (6 papers)Cancer Medicine (4 papers)Nature Communications (4 papers)Oncology Reports (4 papers)
- Partner nations
- ChinaHong KongUnited States
In The Last Decade
Hao Su
129 papers receiving 2.3k citations
Hao Su's Hit Papers
Peers
Comparison fields: 5 of 103
- Hepatology 240
- Cancer Research 296
- Oncology 349
- Molecular Biology 842
- Drug Discovery 3
Countries citing papers authored by Hao Su
This map shows the geographic impact of Hao Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hao Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hao Su more than expected).
Fields of papers citing papers by Hao Su
This network shows the impact of papers produced by Hao Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hao Su. The network helps show where Hao Su may publish in the future.
Co-authors
The 25 scholars most cited alongside Hao Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 139 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 243 | |
| 2 | METTL3 Inhibits Antitumor Immunity by Targeting m6A-BHLHE41-CXCL1/CXCR2 Axis to Promote Colorectal Cancer Hit paper breakdown → | 2022 | 208 |
| 3 | Traditional Medicine Pien Tze Huang Suppresses Colorectal Tumorigenesis Through Restoring Gut Microbiota and Metabolites Hit paper breakdown → | 2023 | 147 |
| 4 | 2020 | 114 | |
| 5 | 2022 | 69 | |
| 6 | 2021 | 62 | |
| 7 | 2018 | 55 | |
| 8 | 2021 | 55 | |
| 9 | 2018 | 49 | |
| 10 | 2023 | 47 | |
| 11 | 2016 | 45 | |
| 12 | 2018 | 34 | |
| 13 | 2018 | 34 | |
| 14 | 2019 | 31 | |
| 15 | 2020 | 31 | |
| 16 | 2021 | 29 | |
| 17 | 2016 | 28 | |
| 18 | 2017 | 28 | |
| 19 | 2022 | 28 | |
| 20 | 2017 | 27 |
About Hao Su
Hao Su is a scholar working on Hepatology, Oncology, Cancer Research, Epidemiology and Molecular Biology, having authored 139 papers that have together received 2.4k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (31 papers), Colorectal Cancer Surgical Treatments (14 papers), Hepatitis B Virus Studies (12 papers), Genetic Associations and Epidemiology (9 papers), RNA modifications and cancer (9 papers), Colorectal Cancer Treatments and Studies (6 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Plant-Microbe Interactions and Immunity (4 papers). The work is most often cited by research in Hepatology (240 citations), Cancer Research (296 citations), Oncology (349 citations), Molecular Biology (842 citations) and Drug Discovery (3 citations). Hao Su has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Huarong Chen, Hongyan Gou, Jun Qing Yu, Tao Peng, Chuangye Han, Guangzhi Zhu, Xiwen Liao, Jianning Zhai, Wei-Xin Liu and Chi-Chun Wong. Their work appears in journals such as Cancer Management and Research, Journal of Cancer, Cancer Medicine, Nature Communications and Oncology Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.